Publications by authors named "Daniel Black Boada"
ESC Heart Fail
September 2024
Article Synopsis
- The study focused on the effects of sotagliflozin, a sodium-glucose co-transporter inhibitor, on heart failure and cardiovascular outcomes in participants with type 2 diabetes, analyzing data from nine randomized controlled trials involving over 15,000 patients.
- Results showed that sotagliflozin significantly reduced the risk of heart failure, stroke, and major adverse cardiovascular events (MACE), with the number needed to treat (NNT) being 20 for heart failure and 26 for MACE.
- Despite its effectiveness, the review faced limitations due to a high risk of bias, suggesting a need for more research comparing sotagliflozin with other SGLT2 inhibitors to
Diabetes Obes Metab
February 2024
Article Synopsis
- The study aimed to assess the renal safety profile and efficacy of sotagliflozin in type 1 and type 2 diabetes patients, focusing on those with or without existing renal issues.
- Fourteen randomized controlled trials involving over 17,500 participants were analyzed, finding no significant changes in renal function or urinary albumin levels due to sotagliflozin treatment.
- While the drug showed no adverse effects on kidney conditions, more research is necessary to fully understand its potential in preventing diabetic kidney disease.
